Impact Of Genomic Medicine Of Healthcare Settings ?

Impact Of Genomic Medicine Of Healthcare Settings

Are you looking for Expert Assignment Writers in the UK? Native Assignment Help boasts a team of highly qualified writers who are ready to assist you with your academic needs. With our commitment to excellence, you can rest assured that your assignments are in good hands.

Introduction - Impact Of Genomic Medicine Of Healthcare Settings

The program in genomic medicine covers all of the aspects of the genomic medicine and science. This will qualify with all of the skills and knowledge to be able to understand and interpret the data of genomic. All of the genomic data helps in increasing the positive impacts on the delivery of service to the community and the patient. Including this aspect, it can be stated that it is one of the important innovations for the healthcare settings mainly in the UK. Due to that reason, the study is mainly focused on the evaluation of the impact of genomic medicine in the healthcare settings in the UK.

Discussion

Genomic medicine as a clinical goal and major factors

Genomic medicine has played an important role in the medical ground that can make great innovations in healthcare settings. As per the statement of Venner et al. (2021), it can be stated that the main goal of genomic medicine is for improving the clinical outcomes by the identification of the patients as a higher risk for some of the specific adverse levels of drug events. This kind of goal can be fulfilled by providing the molecular diagnoses mainly for the “etiological heterogeneous disease” and all of their identification in patients at the expansion lifetime trouble of the disease, which is genetic. As the statement of this author, it can be also stated that some of the major factors presently limit the implementation of genomic medicine. All of those factors have included scarcity of infrastructure for the highest throughput clinical reporting. The second factor is included regulatory requirements for critically protecting the pieces of information, which are related to health. The third factor is included the manual and expensive process for some interpretation of genomic variants. Apart from this, the fourth factor is referred to as requirements of data integration that mainly rely on the formats of primary data, which are very different from each of the sites (Fitipaldi et al. 2018). The fifth factor is based on the low frequency of some findings, which are actionable in some of the disease areas. The sixth factor is included a different burden on the providers for integrating the genetic data among their practices. The seventh factor is included a disinclination which is come from the providers of insurance for covering the test expenses underlying the precision medicine (Venner et al. 2021). All of those kinds of challenges demand that research helps in utilizing the large datasets of genomics, which are connected to the measurement of clinical outcomes for enabling the broad implementation of the medicine, which are genomic (Mehta and Pandit, 2018). Apart from this, many international and national projects of clinical sequencing have been appointed to fulfilling the need for genomic medicine. The genomic data in the “electronic health records” known as EHRs will help in addressing the challenges, which are related to this. All of those data are allowing the researcher for improving and understanding the clinical impact, which is long-term of the genomic data for demonstrating the utility of the outside groups (Venner et al. 2021). All of those data show that genomic medicine helps in holding the great promise of enhancing healthcare but integrating some actionable and searchable genetic data into the health records, which are electronic, remains the challenge. In the UK, an emerging network obtains together clinical laboratories and researchers for investigating the system for the undertaking of genomic medicine. In the UK, the implementation of genomic medicine is relying on the integration of the structure of the genomic data mainly in the EHR system, which helps in enabling the “clinical decision support” that is called CDS.

Response of patients to the intervention of genomic medicine by IGNITE network

The “implementing genomics in practice” that is IGNITE network mainly funds six projects of genomic medicine. Through this varied intervention process, they try to hypothesize the project of synergies across the leveraged for understanding better the experience of the patients with the intervention of genomic medicine. The sixth site of the intervention of genomic medicine by IGNITE projects that the implementation of genomic medicine helps in allowing primary care to the patient by entering family and personal data for generating support for the clinical decisions. The first outcome that has been observed has stated that the patient can receive “risk-concordant care”. As per the statement by Ramirez, (2019), it can be stated that public responses from the baseline to the post-intervention which is quantified only for the attitude towards the intervention of genomic medicine. The sixth exploration of genomic medicine makes a broader impact of genomic medicine on participants in three kinds of areas, which are included attitudes towards the main intervention, plan for sharing the results, and quality of the life. From this project evaluation, it can be stated that there have faced less impact than majorly expected. Younger participants have given a positive or significant attitude toward genomic medicine rather than older people. However, the quality of life among the older has been increased by the implementation of genomic medicine (Tsermpini et al. 2021). In contrast, young people are more attracted to sharing their results rather than the older. From this intervention program, it can be stated that the genomic medicine, which is risk-based, is more likely for this intervention for benefiting the younger individuals (Ginsburg and Phillips, 2018). However, the younger individuals are “coming of age” in the informed era of genomics and help in adopting more views, which are optimistic, which are in general the genomic medicines.

Implementation of genomic medicine in clinical care

In the UK, the PFMGs and GE are mainly aimed at integrating genomics significantly into routine healthcare for improving the diagnosis of cancer and some rare disease and better-personalized target for the treatment options. As per the statement of (Gaille et al. 2021), In the UK, GE is mainly launched more than “100000” genomes project in the year 2012 with the main aim of sequencing more than “100 k” genomes around “85000” NHS patients with some rare disease or mainly cancer. All of those have been delivered since 2014 through more than 13 NHS genomic medicine centres on England. GE is mainly based on a private company that is mainly owned by the social and health care department of the UK, which helps in offering the patients for the potential diagnosis. As well as, it helps in getting some opportunities for taking part in the research. In France, in the case of the implementation of genomic medicine, the PFMG is mainly aimed at the sequence of more than “235000” genomes in the year 2020. The implementation of this approach is mainly used in the improvement of prognosis, diagnosis, and treatment of cancer or some rare diseases like diabetes.

Impact of genomic medicine on clinical care

Genomic medicine has shown that it has a great significance in the treatment of different types of diseases. As per the statement of imperial.ac.uk, (2022), it has a great innovation in the recovery of some major diseases. Genomic medicine helps in improving cancer patient care by refining the cancer prognosis and diagnosis and some alter the quality of life in the individual. The implementation of genomic medicine helps in the development of treatment and drug prescription. The implementation of this treatment helps in dramatically changing the use and testing the pharmaceutical through the stratification of disease. The implementation of genomic medicine helps in suggesting some of the new therapy that helps in some existing application in the repositioning of the drug for clinical trials (ncbi.nlm.nih.gov, 2019). All of those processes are cost-savings and help in avoiding risky and wasteful therapy that helps in providing the setting for the system of healthcare and the large economy. Moreover, it also helps in characterizing and diagnosing genetic diseases. Apart from this genomic medicine also helps in making some potential genomic diagnoses of a disease, which are more effective, and more cost-effective processes. By reducing all over genetic testing with a single analysis, genomic medicine helps in informing individuals all over life. In the treatment of cancer, the treatment of genomics helps in identifying cases that are more aggressive. That helps in guiding some selection of the patients and some adjuvant chemotherapy.

Conclusion

From the above evaluation, it can be concluded that genomic medicine is advancing so rapidly and very quickly, that helps in making some new interventions in the medical practice and helps in sharing information with the patients in the future. In those recent days, the implementation of genomic medicine helps in creating some goals that help in making a great intervention. In future, genomic medicine helps in giving some point of view for data-driven making a decision and helps in providing some data set by the implementation of genomic medicine. Genomic medicine also helps in generating some designing, evidence-based activities, and testing through the implementation of genomic sequencing. Due to that reason, many impacts can be achieved by the implementation of this approach in medical practice. Based on overall representation, it can be stated that genomic medicine can give a great future in the intervention of new types of intervention in recent days and the future in the UK.

References

Journal

Fitipaldi, H., McCarthy, M.I., Florez, J.C. and Franks, P.W., 2018. A global overview of precision medicine in type 2 diabetes.Diabetes, 67(10), pp.1911-1922.

Gaille, M., Horn, R., Bale, M., Bourgain, C., Buchanan, J., Cambon-Thomsen, A., Chneiweiss, H., Clarke, A., Dove, E., Guchet, X. and Hallowell, N., 2021.The ethics of genomic medicine.

Ginsburg, G.S. and Phillips, K.A., 2018. Precision medicine: from science to value.Health Affairs, 37(5), pp.694-701.

Mehta, N. and Pandit, A., 2018.Concurrence of big data analytics and healthcare: A systematic review.International journal of medical informatics, 114, pp.57-65.

Ramirez, A., 2019. IGNITE network: Response of patients to genomic medicine interventions.

Tsermpini, E.E., Al-Mahayri, Z.N., Ali, B.R. and Patrinos, G.P., 2021.Clinical implementation of drug-metabolizing gene-based therapeutic interventions worldwide.Human Genetics, pp.1-21.

Venner, E., Yi, V., Murdock, D., Kalla, S.E., Wu, T.J., Sabo, A., Li, S., Meng, Q., Tian, X., Murugan, M. and Cohen, M., 2021.Neptune: An environment for the delivery of genomic medicine.bioRxiv.